Pfizer’s Karen Bien elected to board of SAFE-BioPharma
Karen Bien, director of business technology on Pfizer’s acquisition, collaboration and divestiture team, has been elected to the board of directors of SAFE-BioPharma Association, the strategic non-profit collaboration that developed and manages the global SAFE-BioPharma digital identity and digital signature standard for the life science and healthcare sectors.
In the volunteer board position, Bien will participate in leading SAFE-BioPharma’s global expansion involving biopharmaceutical industry partners in governments, research institutions and the U.S. healthcare system.
Bien has extensive leadership experience across the pharmaceutical and healthcare industries. At Pfizer, she leads a team that provides technical services and support required for external alliances. She previously held a variety of compliance, continuous improvement and related roles at Wyeth Pharmaceuticals (now Pfizer), Siemens Medical Systems and Innovex.